Adoptive T-cell therapy for Hodgkin lymphoma

Although CAR T-cell therapy is US Food and Drug Administration-approved for B-cell non-Hodgkin lymphomas, the development of adoptive immunotherapy for the treatment of classic Hodgkin lymphoma (cHL) has not accelerated at a similar pace. Adoptive T-cell ther-apy with Epstein-Barr virus-specific cytotoxic T lymphocytes and CD30 CAR T cells have demonstrated significant clinical responses in early clinical trials of patients with cHL. Additionally, CD19 and CD123 CAR T cells that target the immunosuppressive tumor micro-environment in cHL have also been investigated. Here we discuss the landscape of clinical trials of adoptive immunotherapy for patients with cHL with a view toward current chal-lenges and novel strategies to improve the development of CAR T-cell therapy for cHL.

Automated summary

Although CAR T-cell therapy has been approved for B-cell non-Hodgkin lymphomas, the progress for classic Hodgkin lymphoma (cHL) has been slower. Early clinical trials have shown promising clinical responses with the use of Epstein-Barr virus-specific cytotoxic T lymphocytes and CD30 CAR T cells in cHL patients, and research on CD19 and CD123 CAR T cells targeting the immunosuppressive tumor microenvironment in cHL is ongoing.